Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
Recruiting · NCT06643286 · Interventional (participants receive a specific treatment) · Lead sponsor: Erasmus Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.
Who can take part
Inclusion criteria
- 18 years or older
- Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months
Exclusion criteria
- Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma.
- Patients who do not have (sufficient) command of the Dutch language.
Where it is running
4 locations listed.
- Albert Schweitzer hospital - Dordrecht, South Holland, Netherlands
- Erasmus MC - Rotterdam, South Holland, Netherlands
- Franciscus Gasthuis & Vlietland hospital - Rotterdam, South Holland, Netherlands
- Maasstad hospital - Rotterdam, South Holland, Netherlands